Table 2. Treatment effects on serum hormone concentrations.^1-4.

		Con	E+P	E+P+T	ANOVA P value
Estradiol (pg/ml)
2 wk:	2-4hr PD	<5	428.1 ± 64.6b	303.0 ± 57.8b	<0.001
8 wk:	20-28hr PD	<5	25.3 ± 4.9a	16.9 ± 4.4a	0.01
10 wk:	2-4hr PD	<5	366.4 ± 78.8b	239.0 ± 70.5b	<0.001
10 wk:	20-28hr PD	<5	23.3 ± 4.9b	18.6 ± 4.4b	<0.001
16 wk:	20-28hr PD	<5	24.9 ± 5.8b	36.3 ± 5.2b	<0.001
Progesterone (ng/ml)
2 wk:	2-4hr PD	<1	13.2 ± 3.6b	33.7 ± 3.2b,d	<0.001
8 wk:	20-28hr PD	<1	2.8 ± 0.2b	2.6 ± 0.2b	<0.001
10 wk:	2-4hr PD	<1	22.4 ± 2.7b	24.8 ± 2.4b	<0.001
10 wk:	20-28hr PD	<1	3.4 ± 0.4b	3.9 ± 0.3b	<0.001
16 wk:	20-28hr PD	<1	6.6 ± 2.0b	8.9 ± 1.7b	<0.001
Testosterone (ng/dl)
0 wk:	na	12.8 ± 2.7	11.2 ± 2.5	12.8 ± 2.3	0.90
2 wk:	2-4hr PD	6.5 ± 56.0	2.5 ± 52.4	669.1 ± 46.8b,d	<0.001
8 wk:	20-28hr PD	11.4 ± 17.8	8.8 ± 16.6	196.4 ± 14.9b,d	<0.001
10 wk:	2-4hr PD	10.8 ± 19.6	12.8 ± 18.3	128.3 ± 16.4b,d	<0.001
10 wk:	20-28hr PD	7.4 ± 14.8	1.7 ± 13.9	98.1 ± 12.4b,d	<0.001
16 wk:	20-28hr PD	14.5 ± 3.4	11.5 ± 3.2	17.3 ± 2.8	0.47

¹Control = placebo; E = oral 17β-Estradiol; P = oral micronized progesterone; T = testosterone administered via subcutaneous pellets. n = 7, 8, and 10 for Con, E+P, and E+P+T groups, respectively, for all measures.

²Serum was collected 2-4 hrs and/or 20-28 hrs post-dosing (PD) after 2 and 8 weeks of the low-dose T (wk 1-8) and high-dose T (wk 9-16) treatment phases.

³For conversion to SI units, multiply by the following conversion factors: 3.67 for estradiol (pmol/l), 3.18 for progesterone (nmol/l), and 0.035 for testosterone (nmol/l).

⁴Values represent means ± standard error.

⁵Letters indicate significant differences with control group (^a P < 0.05, ^b P < 0.01, ^c P < 0.001) or with E+P group (^d P < 0.01).